An investigation on behalf of investors of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares over potential securities laws violations in connection certain statements was announced.
Investors who purchased shares of Atara Biotherapeutics Inc (NASDAQ:ATRA), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Atara Biotherapeutics Inc (NASDAQ:ATRA) concerning whether certain statements regarding Atara Biotherapeutics Inc’s business, its prospects and its operations were materially false and misleading at the time they were made.
Biotherapeutics Inc (NASDAQ:ATRA) reached $59.89 per share in April 2015, respectively $59.92 per sharein July 2015.
On December 14, 2015, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting (PEW) in patients with end stage renal disease (ESRD). Atara Biotherapeutics Inc said that the trial did not meet its primary endpoint, defined as the percent change from baseline in Lean Body Mass (LBM) as measured by Dual Energy X-Ray Absorptiometry (DXA) at week 12 following weekly treatment with PINTA 745.
Atara Biotherapeutics Inc said that PINTA 745 also did not improve physical function, measures of glycemic control and markers of inflammation. There were no treatment related serious adverse events observed in the trial.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) on December 14, 2015, to as low as $19.50 per share.
On January 15, 2016, NASDAQ:ATRA shares closed at $20.88 per share.
Those who purchased shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego